Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity.
Adult
Female
Humans
Male
Middle Aged
Adiposity
/ genetics
Cross-Sectional Studies
Heart Diseases
Insulin
/ metabolism
Insulin-Like Growth Factor Binding Protein 2
/ blood
Intra-Abdominal Fat
/ metabolism
Liver
/ metabolism
Non-alcoholic Fatty Liver Disease
Obesity
/ metabolism
Obesity, Abdominal
/ blood
ectopic lipid deposition
humans
insulin-like growth factor binding protein-2
liver fat
visceral adiposity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
05
2023
accepted:
05
09
2023
medline:
23
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
Obesity is frequently accompanied by a fatty liver. However, some individuals with high abdominal fat levels nevertheless have low levels of liver fat. Reasons for such discordant phenotypes are unclear. In this paper, we report that among asymptomatic individuals with high levels of visceral fat, low concentrations of IGFBP-2 in the circulation were associated with significantly higher hepatic fat content compared to those with high IGFBP-2 levels. We conclude that quantification of plasma IGFBP-2 concentrations may be useful to identify the early risk for liver fat accumulation in apparently healthy individuals without cardiovascular symptoms. Although excess visceral adiposity (VAT) is generally associated with increased liver fat (LF), recent evidence has revealed heterogeneity in LF content among adults with visceral obesity, potentially contributing to specific differences in cardiometabolic outcomes. Reasons for such discordant VAT-LF phenotypes are largely unknown. The present study aimed at assessing whether circulating levels of insulin growth-factor binding protein-2 (IGFBP-2) could be a useful biomarker in the identification of heterogenous and discordant VAT-LF phenotypes. A sample of 308 middle-aged Caucasian apparently healthy men and women without cardiovascular symptoms were studied for the present cross-sectional analyses. Fasting plasma glucose and lipid levels were assessed and an oral glucose tolerance test was performed. Hepatic fat fraction (HFF) was measured using magnetic resonance spectroscopy whereas VAT was assessed by magnetic resonance imaging. Plasma IGFBP-2 levels were quantified by ELISA. Participants were then classified on the basis of median VAT (81 mL) and IGFBP-2 levels (233 ng/mL). Individuals with high levels of VAT were characterized by higher waist circumference, lower insulin sensitivity, as well as by higher plasma triglyceride and lower HDL-cholesterol levels. Plasma IGFBP-2 levels were inversely correlated with HFF (r = -0.39, In the presence of excess VAT, high IGFBP-2 concentrations are associated with low levels of LF. Although additional studies will be necessary to establish causality and further clarify the clinical implications of these observations, these findings are concordant with a novel function of IGFBP-2 in modulating susceptibility to non-alcoholic fatty liver disease (NAFLD) in the presence of visceral obesity.
Identifiants
pubmed: 37854178
doi: 10.3389/fendo.2023.1222101
pmc: PMC10579942
doi:
Substances chimiques
Insulin
0
Insulin-Like Growth Factor Binding Protein 2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1222101Subventions
Organisme : CIHR
ID : MOP-114820
Pays : Canada
Organisme : CIHR
ID : PJT-148550
Pays : Canada
Organisme : CIHR
ID : FDN-167278
Pays : Canada
Informations de copyright
Copyright © 2023 Rauzier, Chartrand, Alméras, Lemieux, Larose, Mathieu, Pibarot, Lamarche, Rhéaume, Poirier, Després and Picard.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mayo Clin Proc. 2022 Feb;97(2):225-237
pubmed: 34598789
Int J Mol Sci. 2020 Jun 10;21(11):
pubmed: 32532003
Atherosclerosis. 2014 Dec;237(2):645-51
pubmed: 25463100
J Clin Med. 2020 Apr 28;9(5):
pubmed: 32354182
Cardiovasc Diabetol. 2020 Mar 12;19(1):32
pubmed: 32164753
J Int Med Res. 2020 Aug;48(8):300060520935219
pubmed: 32762395
Endocr Connect. 2021 Oct 13;10(10):1315-1325
pubmed: 34524971
Mol Metab. 2019 Jan;19:86-96
pubmed: 30392760
Nutr Diabetes. 2018 Oct 4;8(1):54
pubmed: 30287811
Hum Mol Genet. 2016 Jun 15;25(12):2588-2599
pubmed: 27126637
Nutr Clin Pract. 2020 Feb;35(1):72-84
pubmed: 31840865
Am J Physiol Endocrinol Metab. 2020 Sep 1;319(3):E548-E556
pubmed: 32715747
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
Cell Metab. 2013 Aug 6;18(2):296-302
pubmed: 23931760
Nat Rev Endocrinol. 2020 Mar;16(3):177-189
pubmed: 32020062